Comments
Granules India has received marketing approval from the US Food and Drug Administration (USFDA) for potassium chloride extended release tablets for the treatment of patients with hypokalemia.
Granules’ tablet product is bioequivalent to the reference listed drug (RLD), K-Dur.
“This approval of potassium chloride extended release tablets, a complex MUPS (multi-unit pellet system) based formulation, equivalent to generic “K-Dur,” and “Klor Con M,” is a good addition to our portfolio. We will be launching this product from our Gagillapur site in Hyderabad,’’ Priyanka Chigurupati, Executive Director, Granules Pharma said in a release on Thursday.
ALSO READ:Granules India’s Q2 net surges 71% to ₹164 crore
The drug will be manufactured at the Granules manufacturing facility in Gagillapur, Hyderabad. Granules now have a total of 34 ANDA approvals from the US FDA (32 Final approvals and 2 tentative approvals).
According to IQVIA Health, potassium chloride extended release tablets had US generic sales of approximately $204 million for the most recent 12 months ending August 2020.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.